Arrowhead Pharmaceuticals (MEX:ARWR) Cyclically Adjusted FCF per Share: MXN-5.24 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ARWR Arrowhead Pharmaceuticals Inc MEX:ARWR
49 GF Score
Price MXN454.55
GF Value MXN292.26
! 6 Warning Signs
View Full Analysis

What is Arrowhead Pharmaceuticals Cyclically Adjusted FCF per Share?

Arrowhead Pharmaceuticals MEX:ARWR 49 Cyclically Adjusted FCF per Share is MXN-5.24 as of Jun. 2026. GuruFocus rates MEX:ARWR with a GF Score™ of 49/100 and a GF Value™ of MXN292.26. The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Arrowhead Pharmaceuticals's adjusted free cash flow per share for the three months ended in Jun. 2026 was MXN-22.067. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is MXN-5.24 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -19.80% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -13.10% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 12.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Arrowhead Pharmaceuticals was 35.20% per year. The lowest was -32.00% per year. And the median was 18.85% per year.

As of today (2026-08-26), Arrowhead Pharmaceuticals's current stock price is MXN454.55. Arrowhead Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was MXN-5.24. Arrowhead Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


Arrowhead Pharmaceuticals  (MEX:ARWR) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Arrowhead Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


Arrowhead Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Arrowhead Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arrowhead Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Arrowhead Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.61 -24.13 -17.23 -36.91 -12.92

Arrowhead Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -29.06 -12.92 -6.30 -6.16 -5.24

MEX:ARWR vs AXSM, MDGL, BMRN: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Arrowhead Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arrowhead Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Arrowhead Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


MEX:ARWR
49GF Score
Arrowhead Pharmaceuticals Inc MEX:ARWR
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arrowhead Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Arrowhead Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-22.067/333.9520*333.9520
=-22.067

Current CPI (Jun. 2026) = 333.9520.

Arrowhead Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -3.841 241.428 -5.313
201612 1.357 241.432 1.877
201703 -3.957 243.801 -5.420
201706 -2.797 244.955 -3.813
201709 -2.259 246.819 -3.056
201712 -3.891 246.524 -5.271
201803 -3.418 249.554 -4.574
201806 -3.275 251.989 -4.340
201809 -0.719 252.439 -0.951
201812 34.416 251.233 45.748
201903 -3.915 254.202 -5.143
201906 1.419 256.143 1.850
201909 1.169 256.759 1.520
201912 -5.410 256.974 -7.031
202003 -7.195 258.115 -9.309
202006 -8.060 257.797 -10.441
202009 -2.838 260.280 -3.641
202012 -8.361 260.474 -10.720
202103 50.520 264.877 63.695
202106 -6.414 271.696 -7.884
202109 -6.355 274.310 -7.737
202112 -13.165 278.802 -15.769
202203 10.696 287.504 12.424
202206 -14.905 296.311 -16.798
202209 -19.272 296.808 -21.684
202212 -21.038 296.797 -23.672
202303 -9.831 301.836 -10.877
202306 -10.796 305.109 -11.817
202309 -14.596 307.789 -15.837
202312 -29.471 306.746 -32.085
202403 -17.023 312.332 -18.201
202406 -19.156 314.175 -20.362
202409 -25.572 315.301 -27.085
202412 -25.690 315.605 -27.183
202503 69.179 319.799 72.241
202506 -21.273 322.561 -22.024
202509 1.730 324.800 1.779
202512 1.450 324.054 1.494
202603 10.367 330.213 10.484
202606 -22.067 333.952 -22.067

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of MXN-5.24 mean?
Arrowhead Pharmaceuticals (MEX:ARWR) has a Cyclically Adjusted FCF per Share of MXN-5.24 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Arrowhead Pharmaceuticals and its competitors.
Is Arrowhead Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
Arrowhead Pharmaceuticals' current Cyclically Adjusted FCF per Share is MXN-5.24. Overall, Arrowhead Pharmaceuticals has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Arrowhead Pharmaceuticals' Cyclically Adjusted FCF per Share compare to AXSM and MDGL?
Arrowhead Pharmaceuticals' Cyclically Adjusted FCF per Share of MXN-5.24 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Arrowhead Pharmaceuticals and its competitors. Arrowhead Pharmaceuticals's current Cyclically Adjusted FCF per Share is MXN-5.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arrowhead Pharmaceuticals stock overvalued right now?
Arrowhead Pharmaceuticals (MEX:ARWR) has a current Cyclically Adjusted FCF per Share of MXN-5.24. The stock's GF Value™ is MXN292.26, compared to a current price of MXN454.55 — trading 55.5% above its estimated fair value. The current Cyclically Adjusted FCF per Share is MXN-5.24. Arrowhead Pharmaceuticals' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Arrowhead Pharmaceuticals (MEX:ARWR), the current Cyclically Adjusted FCF per Share is MXN-5.24 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arrowhead Pharmaceuticals (MEX:ARWR) Overvalued in 2026?

Based on GuruFocus' analysis, Arrowhead Pharmaceuticals stock appears to be overvalued. The current stock price of MXN454.55 is trading 55.5% above its estimated GF Value™ of MXN292.26.

Key valuation signals for MEX:ARWR:

  • Cyclically Adjusted FCF per Share: MXN-5.24
  • GF Value™: MXN292.26 vs. price of MXN454.55 (55.5% above fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the MEX:ARWR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Arrowhead Pharmaceuticals Business Description

Address 177 E Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
49GF Score

Get the complete analysis for MEX:ARWR

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN454.55
Price
MXN292.26
GF Value